麻豆国产精品一二三在线观-麻豆国产精品一二三在线观看-麻豆国产精品一区二区-麻豆国产精品永久免费视频-麻豆国产巨作av剧情-麻豆国产蜜桃臀视频在线观看

美國(guó)制藥公司Regeneron Pharmaceuticals  
Schleifer博士在1988年創(chuàng)立了Regeneron制藥公司，并一直擔(dān)任公司董事局主席兼CEO。Regeneron公司擁有數(shù)個(gè)處于開(kāi)發(fā)中的治療腫瘤、眼科疾病和炎癥等多種疾病的產(chǎn)品。

Regeneron is a biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.
Corporate Overview
Founded on the principle that strong science would lead to important new medicines, Regeneron is an integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.

Regeneron Pharmaceuticals, Inc. currently markets ARCALYST? (rilonacept) Injection for Subcutaneous Use for the treatment of a rare, inherited, inflammatory condition. The approval of ARCALYST in 2008 exemplifies Regeneron's commitment to discover, develop and commercialize important medicines for patients suffering from serious diseases.

Currently, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders.

The Company's ability to develop product candidates is enhanced by the application of several proprietary technologies that Regeneron has incorporated into a comprehensive drug discovery and development process. This process is designed to thoroughly understand the biology of specific diseases, discover potential therapeutic candidates, and evaluate these candidates in clinical trials. One specific area of Regeneron expertise is the rapid development of fully-human monoclonal antibodies. In November 2007, Regeneron and sanofi-aventis entered into a global, strategic collaboration to discover, develop, and commercialize fully-human therapeutic antibodies utilizing Regeneron's proprietary VelociSuite? of technologies. Three human antibodies developed under the sanofi-aventis collaboration are in clinical development today, with a goal of advancing an average of two to three new antibodies into clinical development each year.

In addition to the Company's corporate headquarters and research laboratories in Tarrytown, New York, Regeneron has a large-scale biologics manufacturing facility in Rensselaer, New York, where it produces commercial and investigational products for its clinical trials, and a satellite office in Bridgewater, New Jersey.